Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 1/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 1/20 | 1.00 |
| ▸ | CALM1 | P0DP23 | 3/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4736569 | 0.90 | ESR1 (0.82) | ESR1CYP19A1ESR2CALM1POLB | |
| SCHEMBL13084317 | 0.88 | ESR1 (0.78) | ESR1CYP19A1ESR2CALM1POLB | |
| SCHEMBL9202466 | 0.88 | ESR1 (0.78) | ESR1CYP19A1ESR2CALM1IGF1R | |
| Broussonin E SCHEMBL31510414 | 0.85 | CYP19A1 (0.74) | ESR1CYP19A1ESR2CALM1POLB | |
| Broussonin E SCHEMBL6825353 | 0.85 | CYP19A1 (0.74) | ESR1CYP19A1ESR2CALM1POLB | |
| SCHEMBL227115 | 0.85 | ESR1 (0.73) | ESR1CYP19A1ESR2CALM1POLB | |
| SCHEMBL6822966 | 0.83 | ESR1 (0.70) | ESR1CYP19A1ESR2IGF1RALOX15 | |
| SCHEMBL30576426 | 0.83 | ESR1 (0.70) | ESR1CYP19A1ESR2CALM1POLB | |
| SCHEMBL1850095 | 0.83 | ESR1 (0.70) | ESR1CYP19A1ESR2CALM1POLB | |
| SCHEMBL25328659 | 0.82 | ESR1 (0.69) | ESR1CYP19A1ESR2CALM1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195452-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | IATERION, INC. | 2025-06-19 | — | — | US | claimed |
| EP-4561582-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | Iaterion, Inc. (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2024026037-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | IATERION, INC. (US) | 2024-02-01 | — | — | WO | claimed |
| WO-2010120029-A1 | COMPOSITION COMPRISING THE EXTRACT OF ANEMARRHENA ASPHODELOIDES BUNGE OR THE COMPOUNDS ISOLATED FROM THE SAME FOR PREVENTING AND TREATING LIPID METABOLISM DISORDER | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2010-10-21 | — | — | WO | claimed |
| US-6737439-B2 | ACTIVE CANCER CHEMOPREVENTATIVE AND TREATING AGENTS IN MAMMALS, INCLUDING HUMANS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2004-05-18 | — | — | US | claimed |
| US-20030125377-A1 | Aromatase inhibitors from Broussonetia papyrifera | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS THE | 2003-07-03 | — | — | US | claimed |
| WO-2003013554-A2 | AROMATASE INHIBITORS FROM BROUSSONETIA PAPYRIFERA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2003-02-20 | — | — | WO | claimed |
| US-20250195452-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | IATERION, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4561582-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | Iaterion, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-119604294-A | ERbeta estrogenic compounds and methods of use | 益特瑞恩公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2024026037-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | IATERION, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-11857657-B2 | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-109134205-B | Diarylalkanes as potent inhibitors of binuclear enzymes | 尤尼根公司 | 2022-07-19 | — | — | CN | disclosed |
| CN-1993114-A | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN PHARMACEUTICALS INC (US) | 2007-07-04 | — | — | CN | disclosed |
| EP-1748767-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | Unigen Pharmaceuticals, Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005117849-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267047-A1 | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | US | disclosed |
| US-6737439-B2 | ACTIVE CANCER CHEMOPREVENTATIVE AND TREATING AGENTS IN MAMMALS, INCLUDING HUMANS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2004-05-18 | — | — | US | disclosed |
| US-20030125377-A1 | Aromatase inhibitors from Broussonetia papyrifera | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS THE | 2003-07-03 | — | — | US | disclosed |
| WO-2003013554-A2 | AROMATASE INHIBITORS FROM BROUSSONETIA PAPYRIFERA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125377-A1 | Aromatase inhibitors from Broussonetia papyrifera | CYP19A1, HSD17B11, CYP17A1 | ESR1 44/4885CYP19A1 1/4885ESR2 75/4885 |
| US-20050267047-A1 | Diarylalkanes as potent inhibitors of binuclear enzymes | TYR, DDT, HAAO | ESR1 3513/4885CYP19A1 203/4885ESR2 3995/4885 |
| US-20250195452-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | ESR2, ESR1, ESRRB | ESR1 2/4885CYP19A1 9/4885ESR2 1/4885 |
| US-11857657-B2 | Diarylalkanes as potent inhibitors of binuclear enzymes | TYR, DDT, HAAO | ESR1 3513/4885CYP19A1 203/4885ESR2 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.